UPDATED 14:12 EDT / MARCH 14 2025

Tom Doyle, chief technology officer of Medidata Solutions Inc., talks with theCUBE about how AI is transforming medical research, streamlining clinical trials and improving patient outcomes with Medidata Clinical Data Studio at the Tech Innovation CUBEd Awards 2025 series. AI

Reshaping healthcare: The AI-powered future of clinical trials

Artificial intelligence is at the forefront as innovation transforms and reshapes healthcare delivery.

Medidata Solutions Inc.’s Medidata Clinical Data Studio has leaned into that trend by enhancing efficiency, improving data quality and accelerating medical research through automation and AI, according to Tom Doyle (pictured), chief technology officer of Medidata.

“What began as a very paper-based, time-consuming and difficult process for patients, sites, and those medical innovators has evolved quite rapidly into what we see today,” Doyle said. “[It’s now] much more technology forward, more about creating a more seamless experience for patients, for sites and for the sponsors that play such a key role in this important business.”

Doyle spoke with theCUBE’s Rebecca Knight for the Tech Innovation CUBEd Awards 2025 interview series, during an exclusive broadcast on theCUBE, SiliconANGLE Media’s livestreaming studio. They discussed Medidata’s commitment to AI-driven innovation as it equips clinical trials with improved efficiency and accuracy, benefiting both patients and researchers.

How Medidata Clinical Data Studio supercharges medical research

As clinical trials grow more complex with new data sources and sophisticated methodologies, AI helps safeguard data integrity, accelerating decision-making and automating data analysis. Through automation, the Medidata Clinical Data Studio platform enhances data accuracy, reduces manual errors and enables researchers to make faster, more informed decisions, according to Doyle.

“Clinical Data Studio is meant to help in that core part of clinical research, which is about bringing together all the data that’s collected in the course of a clinical trial and synthesizing that in a way that helps us uncover the signals and also make sure that we’ve got a high-quality data set that is demonstrating the safety and efficacy,” he said. “That is the core principle or the core purpose of the [clinical] trial itself.”

The system employs AI-driven anomaly detection to flag irregularities, ensuring the validity of trial results. Additionally, AI-powered language models create intuitive user experiences, helping stakeholders navigate complex datasets in a more human-centric way, according to Doyle. For streamlining the process from ideation to research, development and market availability, Medidata received a CUBEd award for “Top AI-Enabled Product – Healthcare, HealthTech, MedTech.”

“We’ve also looked to AI to transform the way that users interact with the experience,” Doyle said. “Making what can be a very complex process much more human, a more natural way to interrogate data to use generative AI, for example, and the power of language models or large language models to help us understand the history of the data.”

Here’s the complete video interview, part of SiliconANGLE’s and theCUBE Research’s coverage for the Tech Innovation CUBEd Awards 2025 interview series

Photo: SiliconANGLE

A message from John Furrier, co-founder of SiliconANGLE:

Your vote of support is important to us and it helps us keep the content FREE.

One click below supports our mission to provide free, deep, and relevant content.  

Join our community on YouTube

Join the community that includes more than 15,000 #CubeAlumni experts, including Amazon.com CEO Andy Jassy, Dell Technologies founder and CEO Michael Dell, Intel CEO Pat Gelsinger, and many more luminaries and experts.

“TheCUBE is an important partner to the industry. You guys really are a part of our events and we really appreciate you coming and I know people appreciate the content you create as well” – Andy Jassy

THANK YOU